• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

    3/15/23 7:58:00 AM ET
    $BIO
    $PACB
    $QSI
    $TMO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BIO alert in real time by email

    Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations

    Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences' previous CEO, Jason Gammack, will be leaving the company.

    Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quantum-Si (NASDAQ:QSI), a next-generation, single-molecule protein sequencing platform company. Prior to that, he served as CEO of Celsee, a novel single-cell genomics platform company that was acquired by Bio-Rad (NYSE:BIO) in 2020. Earlier in his career, Mr. Stark held senior leadership positions at Life Technologies ((acquired by Thermo Fisher Scientific, NYSE:TMO), Pacific Biosciences (NASDAQ:PACB), and Affymetrix (acquired by Thermo Fisher Scientific).

    "The Board is excited to welcome John to Resolve Biosciences to lead our next chapter of growth and success," said Peer M. Schatz, co-founder and Chairman of the Board. "John brings an impressive track record of execution, operational excellence, and successful team building to drive innovation. Throughout his career, John has consistently delivered high-growth results for numerous industry-defining platforms. We look forward to working with him on our quest to shape the future of spatial biology and realize the massive opportunities and vast applications in science and medicine."

    Mr. Schatz added, "We deeply appreciate Jason Gammack for his contributions and leadership of the company as former CEO, including shepherding the company through the COVID-19 pandemic and initial launch of our commercial platform and service offering."

    "I am honored to join Resolve Biosciences as its next Chief Executive Officer," said Mr. Stark. "It is rare to find an opportunity like this to lead a growing company with a transformative technology and a brilliant and passionate team. I'm looking forward to empowering our global partners and customers with the ability to realize the full potential of our Molecular Cartography technology. We are dedicated to delivering best-in-class products that will enable the understanding of the molecular causes of disease and associated immune response."

    About Resolve Biosciences

    Resolve Biosciences is applying the power of Molecular Cartography™ technology to enable scientists to gain new insights based on the highest-resolution view of spatial biology. The complete system features the company's proprietary, highly multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a fully automated workflow that preserves the sample tissue. The Molecular Cartography technology offers unparalleled sensitivity and specificity to help scientists detect individual transcripts and rare signals to interpret fundamental biology and to rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, infectious disease, and agriculture. Resolve Biosciences is privately held and based in Monheim am Rhein, Germany, with a North American facility and laboratory in San Jose, Calif. For additional information, visit www.resolvebiosciences.com.

    Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005134/en/

    Get the next $BIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BIO
    $PACB
    $QSI
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    Thermo Fisher Scientific Inc
    $TMO
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    Thermo Fisher Scientific Inc
    $TMO
    7/9/2025$460.00Buy → Neutral
    UBS
    Quantum-Si Incorporated
    $QSI
    2/7/2025$3.75Buy
    Alliance Global Partners
    Thermo Fisher Scientific Inc
    $TMO
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    Thermo Fisher Scientific Inc
    $TMO
    12/23/2024Sector Perform
    Scotiabank
    Pacific Biosciences of California Inc.
    $PACB
    11/11/2024Buy → Neutral
    UBS
    Thermo Fisher Scientific Inc
    $TMO
    10/14/2024Buy
    Redburn Atlantic
    More analyst ratings

    $BIO
    $PACB
    $QSI
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Thermo Fisher downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

      7/24/25 9:29:26 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher upgraded by Scotiabank with a new price target

      Scotiabank upgraded Thermo Fisher from Sector Perform to Sector Outperform and set a new price target of $590.00

      7/11/25 7:57:15 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher downgraded by UBS with a new price target

      UBS downgraded Thermo Fisher from Buy to Neutral and set a new price target of $460.00

      7/9/25 8:19:41 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      2/21/25 4:19:32 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:28 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weisler Dion J

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:23:49 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Sperling Scott M

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:21:18 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Keith R. Alexandra

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:18:48 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PacBio HiFi Sequencing Powers First Arab Human Pangenome, Published in Nature Communications

      MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a significant advancement for global genomic equity. Researchers have published the first Arab human pangenome in Nature Communications, powered in large part by PacBio's HiFi long-read sequencing. The study, led by Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, assembled high-resolution genomes from 53 individuals representing diverse Arab populations across eight countries. This study results in millions of newly identified variants and over 111 million base pairs of previously unseque

      7/24/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Joins the 1000 Genomes Long Read Project to Add Isoform Sequencing with Kinnex and Revio

      MENLO PARK, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has joined the 1000 Genomes Long Read Sequencing Project, which will involve contributing long-read transcriptome data to one of the world's most expansive human genomics initiatives. In collaboration with the laboratories of Danny Miller, MD, PhD, Evan Eichler, PhD, at the University of Washington, and Rajiv McCoy, PhD at the McCoy Lab at Johns Hopkins University, PacBio will contribute full-length isoform sequencing using its Kinnex RNA kits and Revio sequencing platform. The collaboration will add Iso-Seq data for appr

      7/23/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    SEC Filings

    See more
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 4:16:06 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 6:03:44 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Quantum-Si Inc (0001816431) (Filer)

      7/7/25 5:13:25 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

      MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

      5/22/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Financials

    Live finance-specific insights

    See more
    • Thermo Fisher Scientific Reports Second Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

      7/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • PacBio to Report Second Quarter 2025 Financial Results on August 7, 2025

      MENLO PARK, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2025 financial results on Thursday, August 7, 2025, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, August 7, 2025, at 5:00 pm ET (2:00 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the "PacBio Q2

      7/21/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2025 on Thursday, July 31, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.b

      7/17/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BIO
    $PACB
    $QSI
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/26/24 8:27:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:52:54 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:48:11 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials